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with minor effect in *2/*2 carriers. After 900mg LD, the effect of the
CYP2C19*2 variant on platelet inhibition was fully compensated in wt/*2 car-
riers but not in *2/*2 carriers (–83.6±25.8% in wt/wt vs. –77.2±26.9% in wt/
*2 vs. –29.5±26.8% in *2/*2; overall p-value=0.0003, p=0.20 for wt/wt versus
wt/*2, p<0.001 for wt/*2 versus *2/*2). A similar pattern was observed for the
active metabolite AUC0-6 and there was a significant correlation between PK
and PD responses irrespective of the LD. 
Conclusion: Carriers of CYP2C19*2 display significant lower responses to
clopidogrel with a gene dose-effect. Clopidogrel resistance can be overcome by
increasing the dose in heterozygous carriers but not in homozygous carriers. 
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Purpose: There is no consensus on how to manage the switch from clopido-
grel to prasugrel immediately after a clopidogrel loading dose (LD). The aim of
this study was to evaluate the pharmacodynamic response of switching patients in
this situation and comparing two prasugrel reloading doses (RD) by using three
laboratory tests. Methods: Patients hospitalized for acute coronary syndrome
(ACS) who received a 300 mg LD of clopidogrel before admission were referred
for inclusion. Their platelet response to the P2Y12 inhibitor was tested with vaso-
dilator-stimulated phosphoprotein phosphorylation (VASP), Verify Now assay
and light transmission aggregometry (LTA) on admission (T1). Then, patients
were immediately randomized for 2 RD of prasugrel (10 mg or 30 mg) and
platelet response was tested again by the same methods (T2). Results: 20 patients
were included in each group. All T1 and T2 analyses were performed during the
first 24 hours after hospitalization. Compared with a 300 mg LD of clopidogrel,
the proportion of patients with platelet hyporesponsiveness for VASP to the
P2Y12 inhibitor was lower after the prasugrel RD: 8 vs 1 (p<0.001) in the 10 mg
prasugrel group and 12 vs none (p<0.001) in the 30 mg prasugrel group. Late ade-
nosine diphosphate-induced platelet aggregation (LPA), by LTA was lower after
a 30 mg prasugrel RD compared with a 10 mg RD (mean LPA 8 +/–9 vs 14 +/–
12; p<0.001). Similar results were found using VerifyNow P2Y12 (mean PRU 38
+/–60 vs 87 +/–71; p < 0.001) and VASP assays (mean PRI 17 +/– 12 vs 33 +/–
15; p<0.001). No bleeding events were reported during the hospital stay. 
Conclusions: For patients receiving 300 mg clopidogrel therapy after an
ACS, a 30 mg RD of prasugrel compared to a 10 mg RD is associated with
further reduction in platelet function and markedly decreases the proportion of
P2Y12 inhibitors low responders.
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Background: Despite encouraging short and mid-term results with drug-
eluting stents (DES) in diabetic (DM) patients (pts) with coronary artery dis-
ease, the long-term efficacy is controversial. We assessed the influence of
long-term dual antiplatelet treatment (DAPLT) with aspirin and clopidogrel on
clinical outcome of DM pts treated with DES. 
Methods: The study included 610 consecutive DM pts (male 80%, mean
age 65±9 years) that had been treated with DES. Five years clinical follow-up
(FU) obtained in 584/610 (96%) of them. At the end of follow-up, 341 (58%)
pts were on DAPLT and 243 (42%) on single antiplatelet treatment (SAPLT).
The primary end-point was the combination of death (D), non-fatal myocardial
infarction (MI) and cerebrovascular accident (CVA), and was considered as
hard end-point (HEP). Stent thrombosis (ST) occurring -12 months after DES
implantation was considered as early (EST), and for >12 months, as late
(LST). The ARC definition for ST was used. 
Results: There was no difference in gender, age, risk factors profile,
unstable coronary artery disease, insulin treatment, extent of coronary artery
disease, and systolic left ventricular function between the two groups. At
12 months post PCI 546 (92%) pts were on DAPLT; the incidence of EST
(definite or probable) was 0.8%. The incidence of LST (definite or probable)
was 0.7%. There was no difference in the incidence of ST in pts treated with
DAPLT vs. SAPLT (1.4% vs. 1.6%, p: ns). At FU, HEP was observed in 18%
vs. 13%, in pts on DAPLT vs. SAPLT (p: ns). 
Conclusion: Long-term DAPLT in DM pts treated with DES implantation
is not associated with better clinical outcome or lower risk of definite or prob-
able ST. 
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Background: Stent thrombosis remains among the most feared complica-
tions of percutaneous coronary intervention (PCI) with stenting. However,
data on its incidence and predictors are sparse and conflicting. 
Objective: We aimed to perform a collaborative systematic review on inci-
dence and predictors of stent thrombosis. PubMed was systematically searched for
eligible studies from the drug-eluting stent (DES) era (1/2002-12/2010).
Methods: Studies were selected if including 2,000 patients undergoing
stenting or reporting on 25 thromboses. Study features, patient characteris-
tics, incidence and predictors of stent thrombosis were abstracted and pooled,
when appropriate, with random-effect methods (point estimate [95% confi-
dence intervals]).
Results: A total of 32 studies were identified (222,752 patients, 4,490 throm-
boses), with DES used in 89%. After a median of 22 months, definite, probable, or
possible stent thrombosis had occurred in 2.3% (2.0%; 2.6%), with acute in 0.3%
(0.2%; 0.5%), subacute in 1.1% (0.9%; 1.3%), late in 0.5% (0.4%; 0.6%), and very
late in 0.6% (0.4%; 0.7%). Similar figures were computed for studies reporting
only on DES, except for lower rates of acute ST (0.2% [0.1%; 0.2%]). From a total
of 47 candidate variables, the most reliable predictors of definite/probable stentPlatelet inhibition tested by Verify Now and VASP
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thrombosis were acute coronary syndrome at admission, diabetes, and stent
number/length. Age, extent of coronary disease, renal failure and smoking also
appeared as significant predictors, but less consistently. Premature discontinuation
of dual antiplatelet therapy was also a powerful predictor of stent thrombosis.
Conclusions: Despite numerous possible risk factors, the strongest predic-
tors of stent thrombosis are diabetes, acute coronary syndromes, stent length/
number, and premature discontinuation of dual antiplatelet therapy.
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Objectives: To assess the impact on 6-month post-stenting outcomes of
long-term vitamin K antagonist (VKA) therapy at baseline and of continued
versus discontinued VKA therapy.
Background: Dual antiplatelet therapy (DAT) after stenting is associated with
higher bleeding event rates in patients on long-term VKA therapy at stenting.
Methods: Matched case-control study in patients who underwent stenting
at four centers between July 2003 and October 2006. Matching was on age,
sex, and clinical presentation.
Results: We included 181 patients on VKA therapy at stenting and 181 con-
trols. VKA therapy was continued after stenting in 60% of the cases. The 6-month
major adverse event rate (primary endpoint defined as the association of death,
myocardial infarction, stent thrombosis, major bleeding or stroke) was signifi-
cantly higher in the cases than in the controls (odds ratio [OR], 3.3; 95% confi-
dence interval [95%CI], 1.5-6.9; P<0.01). The cases had higher rates of death
(OR, 3.8; 95%CI, 1.0-14.0; P=0.05) and major bleeding (OR, 5.4; 95%CI, 1.5-
18.9; P<0.01). DAT duration was significantly shorter in the cases left on VKA
therapy but did not differ according to stent type. By multivariable analysis, sig-
nificant predictors of the MAE rate in the cases were GpIIb3a treatment during
stenting (hazard ratio [HR], 7.4; 95%CI, 1.8-29.7; P<0.01) and age (HR per year
1.05; 95%CI, 1.0-1.1; P=0.03). There was a non significant reduction in MAE and
major bleeding for cases at 6 months if VKA therapy were continued in associa-
tion with DAT after stenting (rate of MAE: 8.3 vs. 15.7% for discontinued VKA
therapy, p=0.26, rate of major bleeding 3.8 vs 9.7 p=0.16). 
Conclusions: Long-term VKA therapy at stenting is associated with
increased bleeding events and poor outcomes. Continued VKA therapy with
close INR monitoring and a short DAT duration may be appropriate in
patients on long-term VKA therapy at stenting.
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Objectives and background: Loss-of-Function allele CYP2C19*2 has
been associated with impaired clopidogrel response and worse prognosis in
clopidogrel-treated patients. Benefit of Tailored therapy according to platelet
function test remains unclear and potential effect of genotypes on this benefit
has not been addressed in unstable patients. The present study was designed
to evaluate the benefit of tailored therapy with higher maintenance dose
according to CYP2C19 genotypes in patients identified as non responders
undergoing Percutaneous Coronary Intervention (PCI) for Non ST segment
Elevation Acute Coronary Syndrome (NSTE ACS). 
Methods and results: 346 consecutive patients were enrolled, who
received loading dose of 600 mg, including 86 *2 Carriers (13 homozygotes
and 73 heterozygotes) and 260 *2 Non Carriers. Clopidogrel response,
assessed with Platelet Reactivity Index VASP (PRI VASP), was significantly
affected by genotypes with lower Clopidogrel Response in CYP2C19*2 allele
carriers (p=0.01). Accordingly, the rate of clopidogrel non responders was
higher in CYP2C19*2 allele carriers: 53% vs. 41%, p=0.04. All Clopidogrel
non Responders (n=151), including 105 *2 Non Carriers and 46 *2 Carriers,
received High 150 mg clopidogrel maintenance at discharge to overcome ini-
tial non response. After one month, High Maintenance dose overcame clopi-
dogrel non response in only 44 % of the whole population and significantly
less frequently in *2 Carriers than in Non Carriers, 28% vs. 50%, p=0.01.
Conclusion: Higher Clopidogrel Maintenance dose was able to overcome
Clopidogrel Non Response in less than half of Clopidogrel Non Responders
undergoing PCI for NSTE ACS. The benefit of this tailored Therapy was sig-
nificantly reduced in CYP2C19*2 Carriers. Therefore, these patients might
require alternative strategies with new P2Y12 blockers.
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Objective: To investigate the relationship between fragmented QRS com-
plex (fQRS) and parameters of infarct size (IS) and no reflow assessed by car-
diac magnetic resonance (CMR) in patients with acute myocardial infarction.
Patients and methods: Patients with a fQRS were compared with patients
without fQRS. CMR was performed in 246 consecutive patients within the
week following the AMI. Early and late gadolinium-enhanced images were
examined to assess IS and microvascular obstruction. Left ventricular ejection
fraction (LVEF) and left ventricular volumes were also determined.
Results: 128 (52%) presented a fQRS on the first 12-lead ECG 36 hours
post-AMI. Despite similar demographic, ECG and clinical features, patients
with a fQRS were more likely to be male and had a higher systolic blood pres-
sure on admission. Furthermore, patients with a fQRS had a significantly
lower LVEF, and larger IS than did patients without fQRS as assessed by
CMR. Interestingly, myocardial perfusion abnormalities after infarction deter-
mined by first-pass perfusion images (microvascular obstruction=MO) and
late perfusion images (persistent MO=PMO) were significantly more frequent
in the fQRS group (Table 1). By multivariate logistic regression analysis, only
infarct size (OR=0.456; 95%CI: 1.03-1.07, p=0.001) was an independent pre-
dictor of a fragmented QRS.Kaplan Meier Curves for MAE
